It says on the bottle take twice a day
InMed Pharmaceuticals utilizes its robust, proprietary biosynthesis process to isolate and create pharmaceutical grade, bio-identical cannabinoids in the laboratory where it can cost-effectively manufacture any of the 90+ cannabinoid compounds at pharmaceutical-grade (greater than 95 percent) purity.
Bioengineers close to brewing opioid …
Additionally, InMed’s biosynthesis process can produce all of the 90+ cannabinoids naturally found in cannabis, enabling the company to avoid the harmful chemicals that are used in the cannabis growing process and offering an easier way to scale-up from the laboratory to full production.
The company’s preclinical development pipeline includes INM-750 for the treatment of epidermolysis bullosa (EB), an orphan pediatric disease with no currently approved therapy.
Only 2-3 cannabinoids can be extracted from the plant in sufficient quantities to make the process economically viable.
Adams adds, "The biosynthesis process opens up access to drug discovery and therapeutic use of all 90+ cannabinoids, most of which occur in only trace amounts in the plant and cannot be extracted in an economical fashion."
InMed plans the following next steps for this promising technology:
Continue to generate new patents for the biosynthesis process leading to 'gateway' and 'downstream' cannabinoids
Optimize and validate system performance criteria with the pilot scale facility at University of British Columbia
Produce at pilot scale several downstream cannabinoids at pharmaceutical-grade purity
Scale-up the pilot production methods to commercial-size facility together with external vendors with extensive biosynthesis expertise
Optimize the commercial system to maximize quantities while minimizing time/cost
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Expand All | Collapse All Anemia (Hb--): fatigue because Hb--
This program and its related IP, when combined with InMed’s proven biosynthesis platform, could place it firmly on the radar of Big Pharma players and other holding firms interested in staking a claim in what could be the next big thing in pain relief, particularly as the opioid crisis continues to grab headlines.
When considering M&A activity within the cannabis industry, the portfolio of specialized holding company CannaRoyalty Corp.
Hypoproliferative anemia (underproduction): low retic anemia
INM-750 contains a combination of biosynthetically-produced cannabinoids carefully selected to modulate levels of the key keratins (proteins) that are absent in EB patients and, thereby, it is hoped, modulate the disease itself.
Megaloblastic anemia (malnutrition): lack Folate, B12 (neuro).
InMed’s approach to developing biosynthetic cannabinoids combines the inherent safety and established efficacy of natural drug structures with the kind of quality-controlled pharmaceutical manufacturing required by the FDA.
Tag Archives: heroin - Picture it..
Companies, like InMed, that use biosynthesis for cannabinoid production can produce all of the active ingredients needed for their drugs in-house, eliminating the huge expenses of cannabis growing facilities and addressing other concerns.
Opiate-Making Yeast Could Lead to "Home-Brewed Heroin…
This approach not only represents a vastly preferable solution compared to orally administered pain relievers, it dovetails perfectly with InMed’s biosynthesis program to produce commercial quantities of cannabinoids for other candidates in is pipeline, which includes INM-750 for the treatment of Epidermolysis Bullosa (genetic condition characterized by fragile, blistering skin), and INM-085 for the treatment of the optic nerve-damaging, degenerative disease glaucoma.
2018/1/4 · Synthetic drugs can be very dangerous
InMed will use its proprietary systems to develop other cannabinoid-based drugs, leveraging its technology to ensure enhanced consistency in production, purity, quality and structural integrity, all of which greatly increase the likelihood of gaining FDA approval for its candidates.
Using computer-based algorithms and proprietary bioinformatics to identify active cannabinoid combinations for the treatment of several diseases in dermatology, ocular disease, pain and other conditions, the company has the capability to advance drug candidates through formulation, preclinical and clinical testing.
InMed’s biosynthesis platform has several other advantages over agriculture-based production methods, including extensive cost savings resulting from not having to contend with the grow-harvest-extract-purify cycle necessary when using cannabis crops.